Back
Header image

Transforming global genetic data into medical decisions

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Latest Scientific News

Glucosylsphingosine is a reliable response biomarker

Perusing our research quest for selective and specific biomarkers we have designed and…

Article with topic Biomarker, Metabolism
Read article

A variant in NUDT2 causes a recessive neurodevelopmental disorder

A recent study on 337 patients with various forms of intellectual disability proposed the…

Article with topic Neurology
Read article

Rapid intravenous enzyme infusion

In the latest issue of American Journal of Hematology, we have published results of recent…

Article with topic Biomarker, Metabolism
Read article

De novo ITPR1 variants are a cause of early-onset ataxia

We explored the clinico-genetic basis of spinocerebellar ataxia 29 (SCA29) by determining…

Article with topic Neurology
Read article

Customer Feedback

Give feedback

Newsletter subscription

CENTOGENE and EVOTEC sign global strategic partnership

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

 Read more
Centogene,

Entrepreneur of the year 2018 in Wismar honored

We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We are...

 Read more
Centogene,

Partnership with the Universities of Greifswald and Rostock

CENTOGENE announced today a partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development of...

 Read more
Centogene,

CENTOGENE to open first U.S. Laboratory in Cambridge, MA

CENTOGENE announced today the opening of its first U.S. based rare disease laboratory in Cambridge, Massachusetts.  The new facility, opening on August 1, 2018,...

 Read more
Centogene,

Mini-symposium at CENTOGENE: „Patient-individualized vaccination in cancer“

CENTOGENE, driving the diagnostic workflows and individualized therapeutic decisions not only in rare diseases but also in oncological setups is proud to host...

 Read more
Centogene,

CENTOGENE to present at the Jefferies 2018 Global Healthcare Conference

CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and accelerate...

 Read more
Centogene,

Agreement with Aldeyra Therapeutics

Collaboration Builds on Genetic Identification of Patients with Sjögren-Larsson Syndrome (SLS) in a Worldwide Cohort Enabling SLS Patients to Benefit from Novel...

 Read more
Centogene,

Dr. Arndt Rolfs talks at ECRD in Vienna

Dr. Arndt Rolfs talks at ECRD about speeding up the rare disease knowledge and information eco-system based on proteomic screening tools

 Read more
Centogene,

Drug development collaboration with Orphazyme

CENTOGENE’s Deep Expertise in Biomarker Identification to Help Guide Clinical Trials

Read more
Centogene,